Hess LM, Rajan N, Winfree K, Davey P, Ball M, Knox H, Graham C. Cost analyses in the US and Japan: a cross-country comparative analysis applied to the PRONOUNCE trial in non-squamous non-small cell lung cancer. Adv Ther. 2015 Dec 9;32(12):1248-62. doi: 10.1007/s12325-015-0270-9
Belozeroff V, Chertow GM, Graham CN, Dehmel D, Parfrey PS, Briggs AH. Economic evaluation of cinacalcet in the United States: the EVOLVE trial. Value Health. 2015 Dec;18(8):1079-87. doi: 10.1016/j.jval.2015.08.007
Graham CN, McBride D, Miles L, Kneidl J, Mollon P. Estimation of indirect (work-related productivity) costs associated with moderate-to-severe plaque psoriasis in Germany. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
Graham C, Knox H, Hess LM, Jen M, Cuyun Carter G, Chandrawansa K, Boye M. Cost-effectiveness in the second-line treatment of non-small cell lung cancer (NSCLC) in the US. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
Klimes J, Mollon P, Graham C, Rajnoch J, Dostal F, Skalicky D, Jordan P, Depta J. Cost-effectiveness analysis of secukinumab compared to ustekinumab in the treatment of moderate to severe plaque psoriasis in the Czech Republic. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
D'Ausilio A, Aiello A, Daniel F, Graham C, Roccia A, Toumi M. A cost-effectiveness analysis of secukinumab 300 mg vs current therapies for the treatment of moderate to severe plaque psoriasis in Italy. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
Auzinger G, Playford GE, Graham CN, Knox HN, Weinstein D, Kantecki M, Schlamm H, Charbonneau C. Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis. BMC Infect Dis. 2015 Oct 26;15:463. doi: 10.1186/s12879-015-1143-1
Graham CN, Hechmati G, Fakih MG, Knox HN, Maglinte GA, Hjelmgren J, Barber B, Schwartzberg LS. Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. J Med Econ. 2015 Aug;18(8):619-28.
Graham CN, Mollon P, Miles L, McBride D. A new cost-effectiveness framework for modeling psoriasis treatment. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.
Earnshaw SR, Graham CN, McDade CL, Spears JB, Kessler CM. Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment. Haemophilia. 2015 May;21(3):310-9. doi: 10.1111/hae.12621
Maglinte G, Graham C, Schwartzberg L, Price T, Knox H, Hechmati G, Hjelmgren J, Barber B, Fakih M. Economic analysis of panitumumab versus cetuximab in chemorefractory patients with wild-type KRAS metastatic colorectal cancer. Poster presented at the 2015 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 9, 2015. San Diego, CA. [abstract] J Manag Care Pharm. 21(4a):S11-2.
Earnshaw SR, McDade CL, Graham CN, Spears J, Kessler C. Economic comparison of treating hemophilia patients who have developed inhibitors via immune tolerance induction versus prophylaxis and on-demand treatment with bypassing agents. Poster presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2013. New Orleans, LA. [abstract] Blood. 2013 Nov 15; 122(21):422. doi: 10.1182/blood.V122.21.422.422
Graham CN, Knox HN, Winfree KB, Hess LM, Liu J, Ortuzar WF. Cost-minimization analysis of pemetrexed/carboplatin with maintenance pemetrexed (PemC) versus paclitaxel/carboplatin/bevacizumab with maintenance bevacizumab (PCB) in nonsquamous non-small cell lung cancer (NS-NSCLC). Poster presented at the Quality Care Symposium of the American Society of Clinical Oncology; November 2013.
Graham C, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating a cost-effectiveness analysis comparing olanzapine with ziprasidone in the treatment of schizophrenia. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 2010. Atlanta, GA. [abstract] Value Health. 2010 May 1; 13(3):A113.
Graham CN, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating an industry-sponsored model comparing the cost-effectiveness of atypical antipsychotics in the treatment of schizophrenia. Schizophr Res. 2010 Apr 1;117(2-3):398-9.
Earnshaw SR, Graham CN, Amonkar MM, Poston SA, Barr CE. Cost-effectiveness of ibandronate intravenous injection in the treatment of US women with postmenopausal osteoporosis. Poster presented at the 2006 American College of Rheumatology Scientific Meeting; November 2006.
Shearer A, Gazzard B, Graham CN, Davis EA, Mauskopf J, Kitahata M, Saag MS, Earnshaw SR. Simulation modeling of adherence and resistance on long-term outcomes in HIV. Poster presented at the Infectious Disease Society of America 44th Annual Meeting; October 15, 2006.
Graham CN, Earnshaw SR, Smith DG, Hogue S, Gitchell J, Marsh H, Becker W, Saunders M. Assessing the impact of smoking cessation therapies on a managed care organization's budget. Poster presented at the Academy of Managed Care Pharmacy Educational Conference; October 7, 2006.
Schnitzler MA, Earnshaw SR, Graham CN, Irish WD, Sato R. Lifetime cost-effectiveness of calcineruin inhibitor-free immunosuppressive treatment after de novo renal transplantation. Poster presented at the World Transplant Congress; July 27, 2006.
Zlateva GP, Javitt JC, Earnshaw SR, Pliel AM, Graham CN, Brogan AJ, Shah S, Adamis AP. Cost-effectiveness model for age-related macular degeneration: comparing early and late Macugen® treatment. Poster presented at the 2006 EURETINA Congress; May 21, 2006. Lisbon, Portugal. Previously presented at the 2005 ISPOR 8th Annual European Congress.
Earnshaw SR, Graham CN, Amonkar MM, Barr C. The cost-effectiveness of ibandronate in the treatment of postmenopausal osteoporosis in the US. Poster presented at the 2006 ISPOR 11th Annual International Meeting; May 20, 2006. Philadelphia, PA. [abstract] Value Health. 2006 May; 9(3):A163.
Earnshaw SR, Graham CN, Amonkar MM, Barr CE. The cost-effectiveness of ibandronate in the treatment of postmenopausal osteoporosis in the US. Value Health. 2006 May 1;9(3):A163.
Javitt JC, Earnshaw SR, Graham CN, Brogan AJ, Zlateva GP, Pleil AM. Cost-effectiveness of Macugen versus no treatment in age-related macular degeneration patients. Poster presented at the Association for Research in Vision and Ophthalmology (ARVO) 2006 Annual Meeting; April 2006.
Javitt JC, Zlateva GP, Earnshaw SR, Pleil AM, Graham CN, Brogan AJ. Cost-effectiveness model for age-related macular degeneration: comparing Macugen® to Visudyne®. Poster presented at the 2006 World Ophthalmology Congress; February 2006. Previously presented at the ISPOR 8th Annual European Congress.
Grzywacz JG, Quandt SA, Early J, Tapia J, Graham CN, Arcury TA. Leaving Family for Work: ambivalence and Mental Health Among Mexican Migrant Farmworker Men. J Immigr Minor Health. 2006 Jan 1;8(1):85-97.